OM:SOBIBiotechs
Tryngolza Data Sharpens Swedish Orphan Biovitrum Severe Hypertriglyceridemia Story
Swedish Orphan Biovitrum (OM:SOBI) reported new Phase 3 data for Tryngolza (olezarsen) in severe hypertriglyceridemia at EAS 2026.
The analysis showed an 85% reduction in acute pancreatitis events in treated patients.
Tryngolza also produced substantial triglyceride lowering in a large, difficult to treat population.
The results add fresh detail to earlier regulatory milestones and expand visibility on efficacy and safety.
Swedish Orphan Biovitrum (OM:SOBI) focuses on rare diseases, and...